76
|
Martínez-Martín P, Rodríguez-Blázquez C, Mario Alvarez, Arakaki T, Arillo VC, Chaná P, Fernández W, Garretto N, Martínez-Castrillo JC, Rodríguez-Violante M, Serrano-Dueñas M, Ballesteros D, Rojo-Abuin JM, Chaudhuri KR, Merello M. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord 2014; 21:50-4. [PMID: 25466406 DOI: 10.1016/j.parkreldis.2014.10.026] [Citation(s) in RCA: 167] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 10/19/2014] [Accepted: 10/27/2014] [Indexed: 10/24/2022]
Abstract
BACKGROUND Severity of PD is usually assessed by means of the motor and disability-based Hoehn and Yahr staging (HY), or clinician and patient global perceptions. Scores of more detailed assessments, as the MDS-UPDRS, have not been translated to a grading that allows assignment of score sections to severity levels. The objective of the present study is to determine cut-off points for PD severity levels based on the MDS-UPDRS. METHODS International, observational study. Applied assessments were: HY, MDS-UPDRS, Clinical Impression for Severity Index, and Clinical and Patient Global Impression of Severity. The coincidence in severity level (mild, moderate, severe) of at least two clinical classifications plus the patient's gradation was considered "the criterion of severity". Cut-off values for each MDS-UPDRS subscale was determined by triangulation of: 1) percentile 90 of the subscale total score; 2) receiver operating characteristic (ROC) analysis; and 3) ordinal logistic regression (OLR) model. RESULTS Sample was composed of 452 consecutive PD patients without dementia, 55.3% males, age 65.1 ± 10.7 years and PD duration 8.7 ± 6.3 years. All HY stages were represented. The "criterion", classified 275 patients (60.8% of the sample) as: mild PD, 149 (54.2%); moderate, 82 (29.8%); and severe, 44 (16%). The following MDS-UPDRS cut-off points between mild/moderate and moderate/severe levels were found: Part 1: 10/11 and 21/22; Part 2: 12/13 and 29/30; Part 3: 32/33 and 58/59; and Part 4: 4/5 and 12/13. CONCLUSION Cut-off points to classify PD patients as mild, moderate, or severe on the basis of their MDS-UPDRS scores are proposed.
Collapse
|
77
|
Andres DS, Cerquetti D, Merello M, Stoop R. Neuronal Entropy Depends on the Level of Alertness in the Parkinsonian Globus Pallidus in vivo. Front Neurol 2014; 5:96. [PMID: 25009529 PMCID: PMC4069479 DOI: 10.3389/fneur.2014.00096] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Accepted: 05/31/2014] [Indexed: 12/02/2022] Open
Abstract
A new working hypothesis of Parkinson's disease (PD) proposes to focus on the central role of entropy increase in the basal ganglia (BG) in movement disorders. The conditions necessary for entropy increase in vivo are, however, still not fully described. We recorded the activity of single globus pallidus pars interna neurons during the transition from deep anesthesia to full alertness in relaxed, head-restrained, control, and parkinsonian (6-hydroxydopamine-lesioned group-lesioned) rats. We found that during awakening from anesthesia, the variation of neuronal entropy was significantly higher in the parkinsonian than in the control group. This implies in our view that in PD the entropy of the output neurons of the BG varies dynamically with the input to the network, which is determined by the level of alertness. Therefore, entropy needs to be interpreted as a dynamic, emergent property that characterizes the global state of the BG neuronal network, rather than a static property of parkinsonian neurons themselves. Within the framework of the "entropy hypothesis," this implies the presence of a pathological feedback loop in the parkinsonian BG, where increasing the network input results in a further increase of neuronal entropy and a worsening of akinesia.
Collapse
|
78
|
Rossi M, Perez-Lloret S, Cerquetti D, Merello M. Movement Disorders in Autosomal Dominant Cerebellar Ataxias: A Systematic Review. Mov Disord Clin Pract 2014; 1:154-160. [PMID: 30363920 DOI: 10.1002/mdc3.12042] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Revised: 04/23/2014] [Accepted: 04/27/2014] [Indexed: 11/06/2022] Open
Abstract
Autosomal dominant cerebellar ataxias (ADCAs) are clinically heterogeneous disorders classified according to genetic subtype and collectively known as SCAs. In a few SCAs, movement disorders can be the most frequent extracerebellar sign. The aim of this article is to perform a systematic review of movement disorders frequency and characteristics in ADCAs. This work consisted of a structured search of electronic databases up to January 2013. Publications containing descriptions of ADCA clinical features written in several languages were selected initially based on title and abstract screening, followed by full-text reading of potentially relevant publications. Clinical findings and demographic data on genetically confirmed patients were extracted. Analysis of individual patient data from subjects with movement disorders was performed using the chi-square test and logistic regression. One thousand and sixty-six publications reviewing 12,151 patients from 30 different SCAs were analyzed. Individual data were available from 755 patients with at least one type of movement disorder during overall disease course. Of 422 patients in whom onset symptom data were available, one third referred a movement disorder as the initial symptom. During overall disease course, parkinsonism was common in many SCA subtypes, frequently described in the absence of ataxia and characterized as responding to dopaminergic medications. Motor complications developed occasionally in some patients as did nigrostriatal imaging alterations. Other frequent features were dystonia, chorea, and myoclonus. Rare conditions, such as akathisia, paroxysmal nonkinesigenic dyskinesia, or stiff person-like syndrome, were also reported. ADCA descriptions included a full range of movement disorders. Aside from postural or intention tremor, dopamine-responsive parkinsonism and dystonia were the most common.
Collapse
|
79
|
Merello M, Bhatia K. From the Reflex Hammer to Molecular Biology: Do Clinical Descriptions Still Play a Role in Our Neurological Decision Making? Jorge Luis Borges and the Analytic Language of Wilkins. Mov Disord Clin Pract 2014; 1:1-2. [PMID: 30363812 DOI: 10.1002/mdc3.12010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Accepted: 02/07/2014] [Indexed: 11/06/2022] Open
|
80
|
Perez-Lloret S, Merello M. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. Expert Opin Pharmacother 2014; 15:1097-107. [PMID: 24673462 DOI: 10.1517/14656566.2014.903924] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION Adenosine A2A receptors are localized in the brain, mainly within the caudate and putamen nuclei of the basal ganglia. Their activation leads to stimulation of the 'indirect' pathway. Conversely, administration of A2A receptor antagonists leads to inhibition of this pathway, which was translated into reduced hypomotility in several animal models of parkinsonism. AREAS COVERED In this review, the effects of two A2A receptor antagonists, istradefylline and tozadenant, on parkinsonian symptoms in animal and humans will be discussed. EXPERT OPINION Animal studies have shown potent antiparkinsonian effects for several A2A receptor antagonists, including istradefylline. In clinical trials, istradefylline reduced OFF time when administered with levodopa, but results are inconclusive. Results with tozadenant are scarce. Modification of thalamic blood flow compatible with reduced inhibition was noted in one small trial, followed by a significant reduction in OFF time in a larger one. Therefore, both drugs show promising efficacy for the reduction of OFF time in levodopa-treated Parkinson's disease patients, but further research is needed in order to obtain definitive conclusions.
Collapse
|
81
|
Rossi M, Perez-Lloret S, Doldan L, Cerquetti D, Balej J, Millar Vernetti P, Hawkes H, Cammarota A, Merello M. Autosomal dominant cerebellar ataxias: a systematic review of clinical features. Eur J Neurol 2014; 21:607-15. [PMID: 24765663 DOI: 10.1111/ene.12350] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE To assess, through systematic review, distinctive or common clinical signs of autosomal dominant cerebellar ataxias (ADCAs), also referred to as spinocerebellar ataxias (SCAs) in genetic nomenclature. METHODS This was a structured search of electronic databases up to September 2012 conducted by two independent reviewers. Publications containing proportions or descriptions of ADCA clinical features written in several languages were selected. Gray literature was included and a back-search was conducted of retrieved publication reference lists. Initial selection was based on title and abstract screening, followed by full-text reading of potentially relevant publications. Clinical findings and demographic data from genetically confirmed patients were extracted. Data were analyzed using the chi-squared test and controlled for alpha-error inflation by applying the Holms step-down procedure. RESULTS In all, 1062 publications reviewing 12 141 patients (52% male) from 30 SCAs were analyzed. Mean age at onset was 35 ± 11 years. Onset symptoms in 3945 patients revealed gait ataxia as the most frequent sign (68%), whereas overall non-ataxia symptom frequency was 50%. Some ADCAs often presented non-ataxia symptoms at onset, such as SCA7 (visual impairment), SCA14 (myoclonus) and SCA17 (parkinsonism). Therefore a categorization into two groups was established: pure ataxia and mainly non-ataxia forms. During overall disease course, dysarthria (90%) and saccadic eye movement alterations (69%) were the most prevalent non-ataxia findings. Some ADCAs were clinically restricted to cerebellar dysfunction, whilst others presented additional features. CONCLUSIONS Autosomal dominant cerebellar ataxias encompass a broad spectrum of clinical features with high prevalence of non-ataxia symptoms. Certain features distinguish different genetic subtypes. A new algorithm for ADCA classification at disease onset is proposed.
Collapse
|
82
|
Antonini A, Calandrella D, Merello M, Koutsikos K, Pilleri M. Effects of rotigotine on Parkinson's disease-related sleep disturbances. Expert Opin Pharmacother 2013; 14:2571-80. [PMID: 24138154 DOI: 10.1517/14656566.2013.849692] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
INTRODUCTION Sleep abnormalities are a frequent non-motor symptom and a prominent cause of disability in patients with Parkinson's disease (PD). AREAS COVERED This review discusses what is currently known about the characteristics of sleep disturbances in PD patients and attempts to clarify the role of dopaminergic pathways in their pathogenesis as well as the beneficial effect of dopaminergic agents in their treatment. In particular, this review will focus on the effects of transdermal rotigotine on improving PD-related sleep disorders. EXPERT OPINION Sleep disturbances are common in PD, and these disturbances can be reduced or resolved, in large part, by preventing or attenuating nocturnal and early morning motor and non-motor symptoms of PD. The studies discussed within this review suggest that sleep disorders are not just a consequence of motor impairment and dopaminergic therapy but are an integral part of the neurodegenerative process of PD. This is supported by the appearance of specific sleep disturbances, which are related to degeneration of the brainstem areas involved in the regulation of sleep/wake states in advance of typical PD symptoms. Development of more detailed diagnostic tools aimed at detecting sleep disturbances and at defining the main causative factors of sleep disturbances in PD will lead to improved treatment of these disturbances.
Collapse
|
83
|
Rossi M, Perez-Lloret S, Doldan L, Cerquetti D, Balej J, Vernetti PM, Hawkes M, Cammarota A, Merello M. Autosomal dominant cerebellar ataxias: A systematic review of clinical features. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.2127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
84
|
Steckiph D, Calabrese G, Bertucci A, Mazzotta A, Vagelli G, Gonella M, Stamopoulos D, Manios E, Papachristos N, Grapsa E, Papageorgiou G, Gogola V, So B, Dey V, Spalding EM, Libetta C, Esposito P, Margiotta E, Maffioli P, Bonaventura A, Bianchi L, Romano D, Rampino T, De Rosa G, Mauric A, Haug U, Enzinger G, Kern-Derstvenscheg E, Sluga A, Ausserwinkler C, Beck W, Rosenkranz AR, Maheshwari V, Haroon S, Loy Y, Samavedham L, Rangaiah GP, Lau T, Stamopoulos D, Mpakirtzi N, Panagiotou M, Barbarousi D, Matsouka C, Grapsa E, Bunani AD, Kowalczyk M, Bartnicki P, Banach M, Rysz J, Lentini P, Zanoli L, Granata A, Contestabile A, Basso A, Berlingo G, Pellanda V, de Cal M, Grazia V, Clementi A, Insalaco M, Dell'Aquila R, Karkar A, Abdelrahman M, Martins AR, Parreira L, Duque AS, Rodrigues I, Baffoun AB, Youssfi MA, Sayeh A, Beji M, Ben Khadra R, Hmida J, Akazawa M, Horiuchi H, Hori Y, Yamada A, Satou H, Odamaki S, Nakai S, Satou K, Aoki K, Saito I, Kamijo Y, Ogata S, Ishibashi Y, Basso F, Wojewodzka-Zelezniakowicz M, Cruz D, Giuliani A, Blanca Martos L, Piccinni P, Ronco C, Potier J, Queffeulou G, Bouet J, Nilsson A, Sternby J, Grundstrom G, Alquist M, Ferraresi M, Di Vico MC, Vigotti FN, Deagostini M, Scognamiglio S, Consiglio V, Clari R, Moro I, Mongilardi E, Piccoli GB, Hancock V, Huang S, Nilsson A, Grundstrom G, Nilsson Ekdahl K, Calabrese G, Steckiph D, Bertucci A, Baldin C, Petrarulo M, Mancuso D, Vagelli G, Gonella M, Inguaggiato P, Canepari G, Gigliola G, Ferrando C, Meinero S, Sicuso C, Pacitti A, Stamopoulos D, Mpakirtzi N, Manios E, Afentakis N, Grapsa E, Tomo T, Matsuyama K, Nakata T, Ishida K, Takeno T, Kadota JI, Minakuchi J, Kastl J, Merello M, Boccato C, Giordana G, Mazzone S, Moscardo V, Kastl J, Giordana G, Reinhardt B, Knaup R, Kruger W, Tovbin D, Kim S, Avnon L, Zlotnik M, Storch S, Umimoto K, Shimamoto Y, Suyama M, Miyata M, Bosch Benitez-Parodi E, Baamonde Laborda EE, Perez G, Ramirez JI, Ramirez Puga A, Guerra R, Garcia Canton C, Lago Alonso MM, Toledo A, Checa Andres MD, Latif FE, Mochida Y, Matsumoto K, Morita K, Tsutsumi D, Ishioka K, Maesato K, Oka M, Moriya H, Hidaka S, Ohtake T, Kobayashi S, Ficheux A, Gayrard N, Duranton F, Guzman C, Szwarc I, Bismuth-Mondolfo J, Brunet P, Servel MF, Argiles A, Tsikliras N, Mademtzoglou S, Balaskas E, Zeid M, Mostafa A, Mowafy MN, Abdo EI, Al Amin OM, Ksiazek A, Zaluska W, Waniewski J, Debowska M, Wojcik-Zaluska A, Elias M, Francois H, Obada E, Lorenzo HK, Charpentier B, Durrbach A, Beaudreuil S, Imamovic G, Marcelli D, Bayh I, Hrvacevic R, Kapun S, Grassmann A, Scatizzi L, Maslovaric J, Daelemans R, Mesens S, Mohamed EA, Wafae A, Kawtar H, Mohamed Amine H, Driss K, Mohammed B. Extracorporeal dialysis: techniques and adequacy - A. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
85
|
Chan HF, Kukkle PL, Merello M, Lim SY, Poon YY, Moro E. Amantadine improves gait in PD patients with STN stimulation. Parkinsonism Relat Disord 2012; 19:316-9. [PMID: 23218842 DOI: 10.1016/j.parkreldis.2012.11.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Revised: 11/03/2012] [Accepted: 11/12/2012] [Indexed: 11/28/2022]
Abstract
In advanced Parkinson's disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients' subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.
Collapse
|
86
|
Nouzeilles M, García M, Rabinowicz A, Merello M. Prospective evaluation of parkinsonism and tremor in patients treated with valproate. Parkinsonism Relat Disord 2012; 5:67-8. [PMID: 18591122 DOI: 10.1016/s1353-8020(99)00013-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/1999] [Revised: 02/22/1999] [Accepted: 02/22/1999] [Indexed: 11/27/2022]
Abstract
We observed a high incidence of postural and intentional tremor in patients exposed to VPA, although not strong enough to interfere with normal life. l-dopa unresponsive parkinsonism was recorded in 10% of patients who received VPA treatment. No correlation with gender, dosage, duration of treatment or concomitant administration of other antiepileptic drugs was observed. The mechanisms for such side effects are unclear. As new GABA mimetic drugs have been postulated to be useful in tremor control [8], it remains paradoxical that VPA should exacerbate such symptomatology by means of a similar mechanism of action.
Collapse
|
87
|
Merello M, Ballesteros D, Rossi M, Arena J, Crespo M, Cervio A, Cuello Oderiz C, Rivero A, Cerquetti D, Risk M, Balej J. Lack of maintenance of gait pattern as measured by instrumental methods suggests psychogenic gait. FUNCTIONAL NEUROLOGY 2012; 27:217-224. [PMID: 23597435 PMCID: PMC3861345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Fluctuation is a common feature of all psychogenic gait disorder (PGD) patterns. Whether this fluctuation involves only the degree of impairment or whether it affects the gait pattern itself remains an interesting question. We hypothesize that, on repeated measurements, both normal and abnormal gait may present quantitative differences while maintaining their basic underlying pattern; conversely, in psychogenic gait, the basic pattern appears not to be preserved. Using an optoelectronic system, data acquired from 19 normal subjects and 66 patients were applied to train a neural network (NN) and subsequently classify gait patterns into four different groups (normal, ataxic, spastic-paraparetic and parkinsonian). Five patients who fulfilled clinical criteria for psychogenic gait and six controls were then prospectively evaluated on two separate occasions, three months apart. Normal controls and ataxic, parkinsonian or spastic patients were correctly identified by the NN, and categorized within the corresponding groups at baseline as well as at a three-month follow-up evaluation. NN analysis showed that after three months, no PGD patient preserved the gait pattern detected at baseline, even though this finding was not clinically apparent. Modification of gait pattern detected by repeated kinematic measurement and NN analysis could suggest the presence of PGD, particularly in difficult-to-diagnose cases.
Collapse
|
88
|
Millar Vernetti P, Perez Lloret S, Rossi M, Cerquetti D, Merello M. Validation of a new scale to assess olfactory dysfunction in patients with Parkinson’s disease. Parkinsonism Relat Disord 2012; 18:358-61. [DOI: 10.1016/j.parkreldis.2011.12.001] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2011] [Revised: 11/29/2011] [Accepted: 12/03/2011] [Indexed: 11/30/2022]
|
89
|
Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG. Wearing-off scales in Parkinson's disease: Critique and recommendations. Mov Disord 2011; 26:2169-75. [DOI: 10.1002/mds.23875] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Accepted: 05/16/2011] [Indexed: 11/12/2022] Open
|
90
|
Starkstein S, Dragovic M, Jorge R, Brockman S, Merello M, Robinson RG, Bruce D, Wilson M. Diagnostic criteria for depression in Parkinson's disease: a study of symptom patterns using latent class analysis. Mov Disord 2011; 26:2239-45. [PMID: 21739470 DOI: 10.1002/mds.23836] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2011] [Revised: 05/15/2011] [Accepted: 05/19/2011] [Indexed: 02/02/2023] Open
Abstract
Although major depression is one of the most frequent psychiatric disorders among patients with Parkinson's disease, diagnostic criteria have yet to be validated. The main aim of our study was to validate depressive symptoms using latent class analysis for use as diagnostic criteria for major depression in Parkinson's disease. We examined a consecutive series of 259 patients with Parkinson's disease admitted to 2 movement disorders clinics for regular follow-ups. All patients were assessed with a comprehensive psychiatric interview that included structured assessments for depression, anxiety, and apathy. The main finding was that all 9 Diagnostic and Statistical Manual (4th edition) diagnostic criteria for major depression (ie, depressed mood, diminished interest or pleasure, weight or appetite changes, sleep changes, psychomotor changes, loss of energy, feelings of worthlessness or inappropriate guilt, poor concentration, and suicidal ideation) identified a patient class (severe depression group) with high statistical significance. Latent class analysis also demonstrated a patient class with minimal depressive symptoms (no-depression group), and a third patient class with intermediate depressive symptoms (moderate depression). Anxiety and apathy were both significant comorbid conditions of moderate and severe depression. Taken together, our findings support the use of the full Diagnostic and Statistical Manual (4th edition) criteria for major depression for use in clinical practice and research in Parkinson's disease and suggest that anxiety may be included as an additional diagnostic criterion.
Collapse
|
91
|
Lloret SP, Nano G, Carrosella A, Gamzu E, Merello M. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurol Sci 2011; 310:248-50. [PMID: 21636098 DOI: 10.1016/j.jns.2011.05.021] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Revised: 04/15/2011] [Accepted: 05/17/2011] [Indexed: 12/16/2022]
Abstract
OBJECTIVE This proof-of-concept, pilot study aimed to explore the safety and anti-sialorrhea efficacy of single doses of intra-oral slow dissolving thin films containing tropicamide (NH004) or placebo. METHODS Nineteen non-demented, idiopathic stable or fluctuating PD patients who complained of sialorrhea received 3 doses (0.3, 1, 3mg) of tropicamide and placebo in random order, separated by 7 days. A 10-cm visual analog scale (VAS) was used to measure the patient's subjective feelings of saliva levels at baseline and at 15, 30, 45, 90 and 120 min after treatment administration. For the last 7 patients, saliva volume was measured at baseline and 75 min after treatment. Fluctuating patients were evaluated in the ON-condition. RESULTS The mean age of included patients was 67±12 years, 78% were male. Median disease duration was 8 years. The mean decrease in VAS score from baseline to 120 min were -0.55±0.54, -1.08±0.54, -1.53±0.52 and -0.81±0.51 for placebo and 0.3, 1 and 3mg tropicamide, respectively (F=0.6 p=0.6, ANOVA). Tropicamide 1mg resulted in a significant VAS score decrease (95%CI: -2.57 to -0.48). Saliva volume was reduced by 27%, 33% or 20% after tropicamide 0.3, 1 or 3mg vs 5% with placebo (p=0.5, Friedman). No adverse events were detected in any of the treatment sequences. DISCUSSION Results of this pilot, proof-of-concept study show that NH004 was safe and exerted antisialorrhea effects worthy of further exploration.
Collapse
|
92
|
Perez Lloret S, Rossi M, Merello M, Rascol O, Cardinali DP. Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study. PARKINSONS DISEASE 2011; 2011:473579. [PMID: 21687754 PMCID: PMC3109353 DOI: 10.4061/2011/473579] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/14/2010] [Revised: 02/24/2011] [Accepted: 03/23/2011] [Indexed: 11/20/2022]
Abstract
Nonmotor symptoms (NMS) like neuropsychiatric symptoms, sleep disturbances or autonomic symptoms are a common feature of Parkinson's disease (PD). To explore the existence of groups of NMS and to relate them to PD characteristics, 71 idiopathic non-demented PD out-patients were recruited. Sleep was evaluated by the PD Sleep Scale (PDSS). Several neuropsychiatric, gastrointestinal and urogenital symptoms were obtained from the NMSQuest. Sialorrhea or dysphagia severity was obtained from the Unified PD Rating Scale activities of daily living section. MADRS depression scale was also administered. Exploratory factor analysis revealed the presence of 5 factors, explaining 70% of variance. The first factor included PDSS measurement of sleep quality, nocturnal restlessness, off-related problems and daytime somnolence; the second factor included nocturia (PDSS) and nocturnal activity; the third one included gastrointestinal and genitourinary symptoms; the forth one included nocturnal psychosis (PDSS), sialorrhea and dysphagia (UPDRS); and the last one included the MADRS score as well as neuropsychiatric symptoms. Sleep disorders correlated with presence of wearing-off, nocturia with age >69 years, and nocturnal psychosis with levodopa equivalent dose or UPDRS II score. Neuropsychiatric symptoms correlated with UPDRS II+III score and non-tricyclic antidepressants. These results support the occurrence of significant NMS grouping in PD patients.
Collapse
|
93
|
Andres DS, Cerquetti DF, Merello M. Turbulence in Globus pallidum neurons in patients with Parkinson's disease: Exponential decay of the power spectrum. J Neurosci Methods 2011; 197:14-20. [DOI: 10.1016/j.jneumeth.2011.01.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Revised: 12/18/2010] [Accepted: 01/20/2011] [Indexed: 10/18/2022]
|
94
|
Perez-Lloret S, Nègre-Pagès L, Ojero-Senard A, Damier P, Destée A, Tison F, Merello M, Rascol O. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort. Eur J Neurol 2011; 19:28-37. [DOI: 10.1111/j.1468-1331.2011.03402.x] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
95
|
Fernandez HH, Merello M. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone? Lancet Neurol 2010; 9:556-7. [PMID: 20452824 DOI: 10.1016/s1474-4422(10)70114-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
96
|
Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG. Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Mov Disord 2010; 25:1131-42. [DOI: 10.1002/mds.23072] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
97
|
Merello M, Fantacone N, Balej J. Kinematic study of whole body center of mass position during gait in Parkinson's disease patients with and without festination. Mov Disord 2010; 25:747-54. [DOI: 10.1002/mds.22958] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
98
|
Lloret SP, Rossi M, Cardinali DP, Merello M. Actigraphic Evaluation of Motor Fluctuations in Patients with Parkinson's Disease. Int J Neurosci 2010; 120:137-43. [DOI: 10.3109/00207450903139663] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
99
|
Santiago PL, Rossi M, Cardinali DP, Merello M. Activity—Rest Rhythm Abnormalities in Parkinson's Disease Patients are Related to Dopaminergic Therapy. Int J Neurosci 2010; 120:11-6. [DOI: 10.3109/00207450903326179] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
100
|
Estévez S, Perez-Lloret S, Merello M. Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD? Int J Neurosci 2010; 119:2257-61. [PMID: 19916854 DOI: 10.3109/00207450903139721] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND The diagnosis of multiple system atrophy (MSA) remains challenging. OBJECTIVE To determine if the occurrence of symptoms of clinical intolerance such as nausea, vomiting, hypotension, and profuse perspiration during a standard acute levodopa challenge may be a useful marker of MSA. METHODS A total of 507 dopaminergic acute challenge tests performed for different purposes in the last 10 years in a movement disorders clinic were reviewed, identifying patients who manifested symptoms of clinical intolerance during test performance. Only those tests completed for diagnostic purposes were included and these were matched by the presence or absence of response to levodopa, sex, and age, with a group of patients undergoing acute challenge without any symptoms of clinical intolerance. Presumptive diagnosis for each patient was performed by means of accepted clinical criteria after a significant follow-up period. Only patients with a final diagnosis of Parkinson's disease (PD) or MSA were analyzed. RESULTS Twenty-three out of the 507 patients (women: 50%) presented symptoms of clinical intolerance and received a final diagnosis of PD or MSA, and underwent further analysis. Four out the 23 patients with intolerance (17%) and one out the 16 patients from the control group (6%) were diagnosed as having MSA (Chi-square = 1.05, p = .3). Overall sensitivity and specificity of the presence of clinical intolerance to predict diagnosis of MSA were 80% (95%IC: 45%-100%) and 44% (95%CI: 27%-61%) respectively. CONCLUSIONS Symptoms of clinical intolerance during an acute levodopa challenge do not appear to be useful in the diagnosis of MSA.
Collapse
|